Overview

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Status:
Terminated

Trial end date:
2016-09-14

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, parallel group, multicenter, outpatient study in COPD subjects who are discharged from the hospital due to a COPD exacerbation. Subjects who meet the eligibility criteria will be randomized to 1 of 2 treatments: arformoterol tartrate inhalation solution (BROVANA) 15 mcg twice daily (BID) or tiotropium bromide (SPIRIVA) 18 mcg once daily (QD), each given for 90 days.

Phase:

Phase 4

Details

Lead Sponsor:

Sunovion

Treatments:

Bromides
Formoterol Fumarate
Pharmaceutical Solutions
Tiotropium Bromide